Turkey In the first fifteen years of the 21st century Turkey saw rapid economic growth, greater access to healthcare, and a boom in pharmaceutical sales. The country’s healthcare sector is now entering a new era of greater govt support for the pharmaceutical industry, more focus on R&D and the potential for…
Turkey Multinational R&D investment in Turkey, particularly investment in clinical trials, has been quite limited relative to the size of the Turkish pharmaceutical market. Turkish R&D spending amounted to just 0.95 percent of GDP last year, but the country plans to reach three percent of GDP by 2023. Multinational R&D investment…
Turkey Over the past six years, Turkey has consistently lowered its drugs prices and guided its companies to greater efficiency. “Reference prices in Turkey are constructed from the lowest price in France, Greece, Italy, Spain or Portugal, converted to Turkish Lira at a rate of TRY 1.9595 per EUR,” says Cem…
Turkey In the coming years, Turkey plans to prioritize R&D initiatives, health studies and medical innovation: that’s the core message Minister of Health Mehmet Müezzinoğlu gave PharmaBoardroom. This is the beginning of a new era for healthcare in Turkey. The twenty-first century has already been a period of change in the…
In the global theater of business and politics, Turkey increasingly leverages its location as an ideal vantage point where actors can seamlessly move between all things West and East. An emerging Asian market with a special relationship to the European Union and close ties with the Middle East, Turkey’s strategic…
Turkey remains a country between two worlds. Not only is it straddled between Asia and Europe, it also boasts a very strong and modern “western” industry and infrastructure together with a more informal economy estimated at 40% of GDP, more typical of an emerging market. Health status does not escape…
See our Cookie Privacy Policy Here